Want to see IN:LAURUSLABS full AI Analyst Report?
LAURUSLABS Stock Chart & Stats
₹1602.30
₹112.20(7.01%)
At close: 4:00 PM EDT
₹1602.30
₹112.20(7.01%)
Day’s Range― - ―
52-Week Range₹913.35 - ₹2,198.10
Previous CloseN/A
Volume7.99M
Average Volume (3M)87.29K
Market Cap
₹1.18T
Enterprise Value₹560.82B
Total Cash (Recent Filing)₹1.14B
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)107.7
Beta0.95
Next Earnings
Oct 29, 2026EPS Estimate
6.67Next Dividend Ex-DateN/A
Dividend Yield0.09%
Share Statistics
EPS (TTM)20.25
Shares Outstanding540,312,200
10 Day Avg. Volume59,713
30 Day Avg. Volume87,288
Financial Highlights & Ratios
PEG Ratio0.41
Price to Book (P/B)10.11
Price to Sales (P/S)7.86
P/FCF Ratio137.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)26.13
Revenue Forecast (FY)₹83.79B
Bulls Say, Bears Say
Bulls Say
Profitability RecoveryThe rebound in revenue and net margin shows that earnings have recovered materially from the prior two years. If profitability remains supported by demand and operating execution, Laurus Labs can rebuild internal funding capacity and strengthen its ability to invest in future growth.
Improving LeverageLower leverage and a rising equity base improve financial resilience and reduce balance-sheet pressure as the company expands. Although absolute debt remains meaningful, the declining debt-to-equity ratio gives Laurus Labs more flexibility to fund operations and manage earnings volatility.
Diversified Pharmaceutical PlatformLaurus Labs combines API manufacturing, finished medicines, and CDMO capabilities, allowing it to participate across multiple stages of the pharmaceutical value chain. This platform can support customer relationships, broaden revenue opportunities, and create durable operating scale across regulated markets.
Bears Say
Weak Free Cash FlowCash conversion remains materially weaker than accounting earnings, with prior negative free cash flow and another sharp decline in FY2026. Continued capital spending or working-capital absorption could restrict financial flexibility and make it harder to fund expansion without relying on debt or other financing.
Gross Margin CompressionThe substantial gross-margin decline suggests that improved net profitability may not yet represent fully restored underlying economics. Persistent input-cost, pricing, or product-mix pressure could limit earnings durability and make future profit growth more dependent on volume or operating efficiencies.
Choppy Growth ProfileThe return to growth is encouraging, but the preceding revenue decline shows that demand and business momentum have not been consistently stable. An uneven top-line profile can complicate capacity planning, reduce operating leverage, and make medium-term earnings performance less predictable.
Laurus Labs Ltd. News
LAURUSLABS FAQ
What was Laurus Labs Ltd.’s price range in the past 12 months?
Laurus Labs Ltd. lowest stock price was ₹913.35 and its highest was ₹2198.10 in the past 12 months.
What is Laurus Labs Ltd.’s market cap?
Laurus Labs Ltd.’s market cap is ₹1.18T.
When is Laurus Labs Ltd.’s upcoming earnings report date?
Laurus Labs Ltd.’s upcoming earnings report date is Oct 29, 2026 which is today.
How were Laurus Labs Ltd.’s earnings last quarter?
Laurus Labs Ltd. released its earnings results on Jul 24, 2026. The company reported ₹6.8 earnings per share for the quarter, beating the consensus estimate of ₹4.912 by ₹1.888.
Is Laurus Labs Ltd. overvalued?
According to Wall Street analysts Laurus Labs Ltd.’s price is currently Overvalued.
Does Laurus Labs Ltd. pay dividends?
Laurus Labs Ltd. pays a Semiannually dividend of ₹1.2 which represents an annual dividend yield of 0.09%. See more information on Laurus Labs Ltd. dividends here
What is Laurus Labs Ltd.’s EPS estimate?
Laurus Labs Ltd.’s EPS estimate is 6.67.
How many shares outstanding does Laurus Labs Ltd. have?
Laurus Labs Ltd. has 540,312,200 shares outstanding.
What happened to Laurus Labs Ltd.’s price movement after its last earnings report?
Laurus Labs Ltd. reported an EPS of ₹6.8 in its last earnings report, beating expectations of ₹4.912. Following the earnings report the stock price went up 2.168%.
Which hedge fund is a major shareholder of Laurus Labs Ltd.?
Currently, no hedge funds are holding shares in IN:LAURUSLABS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Laurus Labs Ltd.
Established in 2005 and headquartered in Hyderabad, India, Laurus Labs Limited, along with its subsidiaries, operates as a diversified global pharmaceutical company. It focuses on the research, manufacturing, and international distribution of a broad spectrum of medicines and active pharmaceutical ingredients (APIs). The company's API and advanced intermediate offerings cover key therapeutic domains such as anti-retroviral (ARV), antidiabetic, cardiovascular, proton pump inhibitors (PPIs), oncology, gastroenterology, and hepatitis C. Additionally, Laurus Labs develops and produces oral solid dosage forms targeting ARV, antidiabetic, cardiovascular, PPI, and central nervous system (CNS) conditions. Beyond its proprietary products, the firm extends its expertise through contract development and manufacturing services for other pharmaceutical enterprises. It also supplies specialized ingredients vital for nutraceutical, dietary supplement, and cosmeceutical applications. Furthermore, Laurus Labs is at the forefront of innovation, engineering novel enzymatic solutions for industrial biotechnology, and providing animal-origin-free recombinant proteins and enzymes for biopharmaceutical use, alongside offering a range of business support services within the pharmaceutical industry.
Technical Analysis
Aurobindo Pharma Ltd
―
Divi's Laboratories Limited
―
Dr. Reddy's Laboratories Ltd.
―
Lupin Limited
―
Sun Pharmaceutical Industries Limited
―